Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Noriko Morita is active.

Publication


Featured researches published by Noriko Morita.


Clinical Genetics | 2012

A prevalent founder mutation and genotype–phenotype correlations of OTOF in Japanese patients with auditory neuropathy

Tatsuo Matsunaga; Hideki Mutai; Shinji Kunishima; Kazunori Namba; Noriko Morimoto; Yukiko Shinjo; Yukiko Arimoto; Y Kataoka; T Shintani; Noriko Morita; Tomoko Sugiuchi; Sawako Masuda; Atsuko Nakano; Hidenobu Taiji; Kimitaka Kaga

Matsunaga T, Mutai H, Kunishima S, Namba K, Morimoto N, Shinjo Y, Arimoto Y, Kataoka Y, Shintani T, Morita N, Sugiuchi T, Masuda S, Nakano A, Taiji H, Kaga K. A prevalent founder mutation and genotype–phenotype correlations of OTOF in Japanese patients with auditory neuropathy.


Gene | 2013

GJB2-associated hearing loss undetected by hearing screening of newborns.

Shujiro Minami; Hideki Mutai; Atsuko Nakano; Yukiko Arimoto; Hidenobu Taiji; Noriko Morimoto; Hideaki Sakata; Nodoka Adachi; Sawako Masuda; Hirokazu Sakamoto; Haruo Yoshida; Fujinobu Tanaka; Noriko Morita; Tomoko Sugiuchi; Kimitaka Kaga; Tatsuo Matsunaga

The hearing loss caused by GJB2 mutations is usually congenital in onset, moderate to profound in degree, and non-progressive. The objective of this study was to study genotype/phenotype correlations and to document 14 children with biallelic GJB2 mutations who passed newborn hearing screening (NHS). Genetic testing for GJB2 mutations by direct sequencing was performed on 924 individuals (810 families) with hearing loss, and 204 patients (175 families) were found to carry biallelic GJB2 mutations. NHS results were obtained through medical records. A total of 18 pathological mutations were identified, which were subclassified as eight inactivating and 10 non-inactivating mutations. p.I128M and p.H73Y were identified as novel missense GJB2 mutations. Of the 14 children with biallelic GJB2 mutations who passed NHS, eight were compound heterozygotes and 3 were homozygous for the c.235delC mutation in GJB2, and the other three combinations of non-c.235delC mutations identified were p.Y136X-p.G45E/p.V37I heterozygous, c.512ins4/p.R143W heterozygous, and p.V37I/p.R143W heterozygous. These 14 cases demonstrate that the current NHS does not identify all infants with biallelic GJB2 mutations. They suggest that the frequency of non-penetrance at birth is approximately 6.9% or higher in DFNB1 patients and provide further evidence that GJB2 hearing loss may not always be congenital in onset.


Acta Oto-laryngologica | 2013

Genetic analysis of PAX3 for diagnosis of Waardenburg syndrome type I

Tatsuo Matsunaga; Hideki Mutai; Kazunori Namba; Noriko Morita; Sawako Masuda

Abstract Conclusion: PAX3 genetic analysis increased the diagnostic accuracy for Waardenburg syndrome type I (WS1). Analysis of the three-dimensional (3D) structure of PAX3 helped verify the pathogenicity of a missense mutation, and multiple ligation-dependent probe amplification (MLPA) analysis of PAX3 increased the sensitivity of genetic diagnosis in patients with WS1. Objectives: Clinical diagnosis of WS1 is often difficult in individual patients with isolated, mild, or non-specific symptoms. The objective of the present study was to facilitate the accurate diagnosis of WS1 through genetic analysis of PAX3 and to expand the spectrum of known PAX3 mutations. Methods: In two Japanese families with WS1, we conducted a clinical evaluation of symptoms and genetic analysis, which involved direct sequencing, MLPA analysis, quantitative PCR of PAX3, and analysis of the predicted 3D structure of PAX3. The normal-hearing control group comprised 92 subjects who had normal hearing according to pure tone audiometry. Results: In one family, direct sequencing of PAX3 identified a heterozygous mutation, p.I59F. Analysis of PAX3 3D structures indicated that this mutation distorted the DNA-binding site of PAX3. In the other family, MLPA analysis and subsequent quantitative PCR detected a large, heterozygous deletion spanning 1759–2554 kb that eliminated 12–18 genes including a whole PAX3 gene.


Laryngoscope | 2017

Frequency and specific characteristics of the incomplete partition type III anomaly in children

Ayako Kanno; Hideki Mutai; Kazunori Namba; Noriko Morita; Atsuko Nakano; Noboru Ogahara; Tomoko Sugiuchi; Kaoru Ogawa; Tatsuo Matsunaga

To determine the frequency of the incomplete partition type III anomaly and the genetic and clinical features associated with POU3F4 mutations in children with hearing loss.


Audiology Japan | 2009

Rehabilitation in children with hearing loss

Hiroshi Yamashita; Noriko Morita; Naoko Ujita


Audiology Japan | 2004

Problems and Considerations in Newborn Hearing Screening

Noriko Morita; Shigehiko Itou; Satoru Yamaguchi


Orphanet Journal of Rare Diseases | 2017

Prevalence of TECTA mutation in patients with mid-frequency sensorineural hearing loss

Nobuko Yamamoto; Hideki Mutai; Kazunori Namba; Noriko Morita; Shin Masuda; Yasuyuki Nishi; Atsuko Nakano; Sawako Masuda; Masato Fujioka; Kimitaka Kaga; Kaoru Ogawa; Tatsuo Matsunaga


Audiology Japan | 1999

Auditory Screening System for Three-Year-Old Children. Part 2. Some of the Factors Responsible for Missing of Children's Hearing Impairment Problems and the Effect of Treatment and Education.

Noriko Morita; Mikio Hiraiwa


Nippon Jibiinkoka Gakkai Kaiho | 2018

Nationwide Survey of Hearing Loss Caused by Mumps during 2015-2016 in Japan

Noriko Morimoto; Shin Masuda; Shin Aso; Akinori Kashio; Yukihiko Kanda; Misao Nakazawa; Noriko Morita; Takashi Nakagawa; Kazunori Nishizaki


Ear and Hearing | 2018

Deterioration in Distortion Product Otoacoustic Emissions in Auditory Neuropathy Patients With Distinct Clinical and Genetic Backgrounds

Kyoko Kitao; Hideki Mutai; Kazunori Namba; Noriko Morimoto; Atsuko Nakano; Yukiko Arimoto; Tomoko Sugiuchi; Sawako Masuda; Yasuhide Okamoto; Noriko Morita; Hirokazu Sakamoto; Tomoko Shintani; Satoshi Fukuda; Kimitaka Kaga; Tatsuo Matsunaga

Collaboration


Dive into the Noriko Morita's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Tatsuo Matsunaga

International University of Health and Welfare

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kimitaka Kaga

International University of Health and Welfare

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Yukiko Arimoto

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Hirokazu Sakamoto

Boston Children's Hospital

View shared research outputs
Researchain Logo
Decentralizing Knowledge